What is the old name for Soleno Therapeutics?
Soleno Therapeutics, Inc. was originally incorporated in Delaware under the name Capnia, Inc. before undergoing a major strategic pivot and corporate rebranding. Founded initially as a medical device company focusing primarily on neonatal health care products and diagnostic tools, the enterprise later shifted its core operational mission toward biopharmaceuticals and rare disease therapeutics. A pivotal milestone occurred when Capnia completed a merger with Essentialis, Inc., a clinical-stage pharmaceutical firm specializing in treatments for severe metabolic conditions like Prader-Willi syndrome. Following this transaction, management elected to change the corporate name to Soleno Therapeutics to better communicate its new focus on developing specialized drug therapies, eventually leading to major clinical breakthroughs and regulatory approvals for its flagship treatments.
Related FAQs
SmartBank operates as a growing commercial community bank serving regions across the Southeastern United States, establishing a distinct operating model when evaluated against national banking mega-corporations.
VYKAT XR (diazoxide choline extended-release tablets), developed by Soleno Therapeutics, received FDA approval as an essential oral treatment indicated to manage severe hyperphagia in adult and pediatric patients aged 4 years and older with Prader-Wi...
Neurocrine Biosciences completed a definitive acquisition agreement to purchase Soleno Therapeutics for a total equity valuation of approximately 2.9 billion dollars in cash.
Lucid Group, traded under the ticker LCID, maintains a market capitalization fluctuating around the multi-billion-dollar range.
Soleno Therapeutics, Inc. reports a trailing twelve-month revenue of approximately $190.
Soleno Therapeutics operates as a fully transparent, SEC-registered public biotechnology corporation listed on major stock exchanges, adhering strictly to federal reporting standards, corporate governance rules, and pharmaceutical industry regulation...
Mind Medicine, commonly known as MindMed, commands a multi-billion-dollar market capitalization, reflecting high investor enthusiasm within the clinical-stage biopharmaceutical sector.
Soleno Therapeutics, Inc. maintains a specialized market capitalization valued in the tens of millions to over a hundred million U.S. dollars, reflecting its status as a clinical-stage biopharmaceutical enterprise.
Hyperphagia, an abnormally intense and persistent sensation of hunger often associated with rare genetic disorders like Prader-Willi syndrome, has historically relied primarily on strict environmental food security and behavioral management.
Soleno Therapeutics Inc, trading under the ticker symbol SLNO, was a publicly traded biopharmaceutical company listed on the Nasdaq stock exchange.
Investing in NIO involves assessing its position as an early pioneer and technology leader in premium smart electric vehicles and automated battery exchange services.
Soleno Therapeutics Inc, trading under the ticker SLNO, is a biopharmaceutical company that has drawn significant market attention following major corporate acquisition developments and the successful commercial launch of its flagship therapeutic pro...
Class-action lawsuits involving Soleno Therapeutics, Inc.
Soleno Therapeutics achieved a major regulatory milestone when its flagship lead product candidate, VYKAT XR extended-release tablets, received official approval from the United States Food and Drug Administration.